Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer.
James Thomas Symanowski
Consultant or Advisory Role - Endocyte
Elzbieta Kutarska
Research Funding - Nazwa Sponsora
Mariusz Bidzinski
No relevant relationships to disclose
Binh Nguyen
Employment or Leadership Position - Endocyte
Stock Ownership - Endocyte
Research Funding - Endocyte
Reshma A. Rangwala
Employment or Leadership Position - Merck
Stock Ownership - Merck
R. Wendel Naumann
Research Funding - Endocyte